Switch theme
Sign up to access all valuation multiples
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
2005
59
LTM Revenue $15K
LTM EBITDA -$107M
$226M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Altimmune has a last 12-month revenue of $15K and a last 12-month EBITDA of -$107M.
In the most recent fiscal year, Altimmune achieved revenue of $20K and an EBITDA of -$94.8M.
Altimmune expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Altimmune valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.4M | $20K | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$87.9M | -$94.8M | XXX | XXX | XXX |
| EBITDA Margin | -20642% | -474060% | XXX | XXX | XXX |
| Net Profit | -$84.7M | -$88.4M | XXX | XXX | XXX |
| Net Margin | -19886% | -442235% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Altimmune's stock price is $5.
Altimmune has current market cap of $357M, and EV of $226M.
See Altimmune trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $226M | $357M | XXX | XXX | XXX | XXX | $-1.37 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Altimmune has market cap of $357M and EV of $226M.
Altimmune's trades at 15022.3x LTM EV/Revenue multiple, and -2.1x LTM EBITDA.
Analysts estimate Altimmune's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Altimmune and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $226M | XXX | XXX | XXX |
| EV/Revenue | 11318.2x | XXX | XXX | XXX |
| EV/EBITDA | -2.4x | XXX | XXX | XXX |
| P/E | -3.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAltimmune's NTM/LTM revenue growth is -80%
Altimmune's revenue per employee for the last fiscal year averaged $0K, while opex per employee averaged $1.7M for the same period.
Over next 12 months, Altimmune's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Altimmune's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Altimmune and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -95% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -474060% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -474140% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 104830% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 411130% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 515960% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Altimmune acquired XXX companies to date.
Last acquisition by Altimmune was XXXXXXXX, XXXXX XXXXX XXXXXX . Altimmune acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Altimmune founded? | Altimmune was founded in 2005. |
| Where is Altimmune headquartered? | Altimmune is headquartered in United States of America. |
| How many employees does Altimmune have? | As of today, Altimmune has 59 employees. |
| Who is the CEO of Altimmune? | Altimmune's CEO is Dr. Vipin K. Garg, PhD. |
| Is Altimmune publicy listed? | Yes, Altimmune is a public company listed on NAS. |
| What is the stock symbol of Altimmune? | Altimmune trades under ALT ticker. |
| When did Altimmune go public? | Altimmune went public in 2005. |
| Who are competitors of Altimmune? | Similar companies to Altimmune include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Altimmune? | Altimmune's current market cap is $357M |
| What is the current revenue of Altimmune? | Altimmune's last 12-month revenue is $15K. |
| What is the current EBITDA of Altimmune? | Altimmune's last 12-month EBITDA is -$107M. |
| What is the current EV/Revenue multiple of Altimmune? | Current revenue multiple of Altimmune is 15022.3x. |
| What is the current EV/EBITDA multiple of Altimmune? | Current EBITDA multiple of Altimmune is -2.1x. |
| What is the current revenue growth of Altimmune? | Altimmune revenue growth between 2023 and 2024 was -95%. |
| Is Altimmune profitable? | Yes, Altimmune is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
